LENZ Therapeutics, Inc. (LENZ): Total Liabilities
$21.54M
As of 2025-12-31
$17.33M
As of 2026-06-30
-5.6%
3-year compound annual growth
-7.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.54M | +92.0% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $11.22M | -43.0% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $19.70M | -23.1% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $25.61M | +42.8% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $17.94M | -44.6% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $32.36M | n/a | 2022-03-21, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
Compare LENZ, ALEC, PTHS, RLAY side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗